Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of herombopag olamine tablets for thrombocytopenia in chronic liver disease patients undergoing elective invasive procedures
CTR20242559Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hetrombopag in Thrombocytopenia, chronic liver disease (CLD), sponsored by Hengrui Therapeutics. Started Jul 2024; status: completed.
02
Drugs
hetrombopag
03
Conditions
Thrombocytopeniachronic liver disease (CLD)
Beyond the preview
Go deeper on CTR20242559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242559.